Suzhou-based Sinovent Inc. has announced the enrollment of its first patient in a Phase III clinical study for XNW3009, a novel gout drug candidate designed to inhibit the human urate transporter 1 (URAT1) and address gout-related hyperuricemia.
Founded in 2016, Sinovent operates across multiple locations, including Beijing, Shanghai, Australia, and Boston, U.S. The company boasts a diverse pipeline featuring various therapeutic programs, including BLI inhibitors, EZH2 inhibitors, hURAT1 inhibitors, and next-generation antibody-drug conjugates (ADCs), targeting conditions such as tumors, infectious diseases, metabolic disorders, and autoimmune diseases.- Flcube.com
